Gen-Probe/DiagnoCure
This article was originally published in The Gray Sheet
Executive Summary
136-patient study assessing DiagnoCure's urine-based prostate cancer diagnostic incorporating the PCA3/DD3 genetic marker shows sensitivity of 67%, specificity of 83% and negative predictive value of 90%, according to the Canadian firm. Study results were presented during the American Urological Association meeting in San Antonio May 22-26. The PCA3 assay is licensed to Gen-Probe (1"The Gray Sheet" Nov. 24, 2003, In Brief)...